Korean Drug Co., Ltd

As of March 31, 2026, Korean Drug Co., Ltd carries a market capitalization of 42.81B, placing it among publicly traded companies globally. Its enterprise value stands at 8.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Korean Drug Co., Ltd has 10.82M shares outstanding.

As of March 31, 2026, Korean Drug Co., Ltd trades at a trailing price-to-earnings ratio of 6.19. The price-to-sales ratio is 0.68, and the price-to-book ratio stands at 0.52.

As of March 31, 2026, Korean Drug Co., Ltd trades at an EV/EBITDA multiple of 0.90 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.13 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 1.15 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Korean Drug Co., Ltd trades at an EV/FCF ratio of 0.79, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 8.35B versus a market cap of 42.81B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Korean Drug Co., Ltd maintains a current ratio of 6.63, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.10, indicating conservative leverage, while an interest coverage ratio of 2,340.40 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Korean Drug Co., Ltd posted a return on equity (ROE) of 8.67, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.56 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.38, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.66, useful for judging operating efficiency across full business cycles. The company generates approximately 259.88M in revenue per employee across its workforce of 241.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.91 indicates how many times Korean Drug Co., Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Korean Drug Co., Ltd recorded 1.43B in income tax expense. That works out to an effective tax rate of 17.14, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 8.34B, leaving 6.91B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Korean Drug Co., Ltd's stock has declined approximately 30.67% over the past 52 weeks. The 50-day moving average sits at 3,328.60, while the 200-day moving average is 3,689.53.

Over the twelve months ended March 31, 2026, Korean Drug Co., Ltd generated 62.76B in revenue and converted that into 6.91B in net income, yielding earnings per share of 638.80. EBITDA reached 9.25B, while operating income came in at 7.29B.

As of March 31, 2026, Korean Drug Co., Ltd holds 34.54B in cash and equivalents against 83.07M in total debt, resulting in a net debt position of -9.40B. Total book value stands at 82.31B, with working capital of 61.18B providing operational flexibility.

Korean Drug Co., Ltd produced 11.10B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -481.86M in capital expenditures, free cash flow totaled 10.62B - equivalent to 981.31 per share.

Over the twelve months ended March 31, 2026, Korean Drug Co., Ltd posted a gross margin of 43.71, reflecting its pricing power and cost economics. The operating margin of 11.61 and net profit margin of 11.01 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Korean Drug Co., Ltd paid dividends of 179.99 per share. The dividend payout ratio of 28.18 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 24.81, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.65, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Korean Drug Co., Ltd shareholders.

Korean Drug Co., Ltd's most recent stock split took place on April 25, 2006 with a 1:10 split ratio.

As of March 31, 2026, Korean Drug Co., Ltd has an Altman Z-Score of 4.58, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.